{"id":43410,"date":"2025-10-15T15:42:31","date_gmt":"2025-10-15T07:42:31","guid":{"rendered":"https:\/\/flcube.com\/?p=43410"},"modified":"2025-10-15T15:42:32","modified_gmt":"2025-10-15T07:42:32","slug":"johnson-johnson-reports-robust-q3-2025-sales-growth-boosts-full%e2%80%91year-outlook","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43410","title":{"rendered":"Johnson &amp; Johnson Reports Robust Q3\u202f2025 Sales Growth, Boosts Full\u2011Year Outlook"},"content":{"rendered":"\n<p>Johnson &amp; Johnson (J&amp;J, <a href=\"https:\/\/www.google.com\/finance\/quote\/JNJ:NYSE\">NYSE: JNJ<\/a>) announced its third\u2011quarter results for 2025, showing a <strong>5.4\u202f% year\u2011on\u2011year (YoY) increase in constant\u2011currency sales<\/strong> to <strong>USD\u202f23.99\u202fbillion<\/strong>. The U.S. market grew 6.2\u202f% to <strong>USD\u202f13.7\u202fbillion<\/strong>, while international markets rose 4.4\u202f% to <strong>USD\u202f10.29\u202fbillion<\/strong>. Chief Executive Officer Joaquin\u202fDuato described the company as entering \u201ca new era of accelerated growth and innovation\u201d thanks to its expanding drug and device portfolio.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-highlights\">Financial Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q3\u202f2025<\/th><th>YoY Change<\/th><th>Notes<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Group Sales<\/strong><\/td><td>USD\u202f23.99\u202fB<\/td><td>+5.4\u202f%<\/td><td>Constant\u2011currency<\/td><\/tr><tr><td><strong>U.S. Sales<\/strong><\/td><td>USD\u202f13.70\u202fB<\/td><td>+6.2\u202f%<\/td><td><\/td><\/tr><tr><td><strong>International Sales<\/strong><\/td><td>USD\u202f10.29\u202fB<\/td><td>+4.4\u202f%<\/td><td><\/td><\/tr><tr><td><strong>Full\u2011Year Guidance<\/strong><\/td><td>3.5\u202f%\u20134.0\u202f%<\/td><td>Raised from 3.2\u202f%\u20133.7\u202f%<\/td><td>+USD\u202f300\u202fM to USD\u202f93.0\u202fB\u201393.4\u202fB<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-business-unit-performance\">Business Unit Performance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Unit<\/th><th>Q3 Sales (USD\u202fB)<\/th><th>YoY Growth<\/th><th>Comments<\/th><\/tr><\/thead><tbody><tr><td><strong>Innovative Medicines<\/strong><\/td><td>15.56<\/td><td>+5.3\u202f%<\/td><td>Strong oncology &amp; immunology drivers<\/td><\/tr><tr><td><strong>MedTech<\/strong><\/td><td>8.43<\/td><td>+5.6\u202f%<\/td><td>Sustained device pipeline momentum<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pharma-unit-highlights\">Pharma Unit Highlights<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-oncology-19-2-to-usd-6-53-b\">Oncology \u2013 +19.2\u202f% to USD\u202f6.53\u202fB<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Darzalex<\/strong> (daratumumab) \u2013 +19.9\u202f% to USD\u202f3.67\u202fB<\/li>\n\n\n\n<li><strong>Carvykti<\/strong> (ciltacabtagene autoleucel) \u2013 +81.4\u202f% to USD\u202f524\u202fM<\/li>\n\n\n\n<li><strong>Erleada<\/strong> (apalutamide) \u2013 +15.3\u202f% to USD\u202f936\u202fM<\/li>\n\n\n\n<li><strong>Rybrevant\u202f+\u202fLazcluse<\/strong> combo \u2013 USD\u202f198\u202fM, >\u202f2\u00d7 YoY<\/li>\n\n\n\n<li><strong>Imbruvica<\/strong> \u2013 \u221210.6\u202f% to USD\u202f695\u202fM<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-immunology-10-6-to-usd-4-17-b\">Immunology \u2013 \u221210.6\u202f% to USD\u202f4.17\u202fB<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Tremfya<\/strong> (guselkumab) \u2013 +40.1\u202f% to USD\u202f1.42\u202fB<\/li>\n\n\n\n<li><strong>Simponi\/Simponi\u202fAria<\/strong> \u2013 +31.5\u202f% to USD\u202f687\u202fM<\/li>\n\n\n\n<li><strong>Stelara<\/strong> (ustekinumab) \u2013 \u221242\u202f% to USD\u202f1.57\u202fB (biosimilar pressure)<br><em>Excluding Stelara, overall pharma grew 16\u202f% YoY.<\/em><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-neuroscience-14-6-to-usd-2-02-b\">Neuroscience \u2013 +14.6\u202f% to USD\u202f2.02\u202fB<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Spravato<\/strong> (esketamine) \u2013 +60.8\u202f% to USD\u202f459\u202fM<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-developments\">Pipeline Developments<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Icotrokinra<\/strong> \u2013 First\u2011in\u2011class oral IL\u201123 receptor blocker; Phase\u202fIIb ANTHEM\u2011UC study achieved 63.5\u202f% clinical response at 400\u202fmg vs. 27\u202f% placebo (p\u202f&lt;\u202f0.001).<br><em>Potential oral alternative to injected biologics for ulcerative colitis.<\/em><\/li>\n\n\n\n<li><strong>NDA Filing<\/strong> \u2013 July\u202f2025 for moderate\u2011to\u2011severe plaque psoriasis; additional indications in Crohn\u2019s disease and psoriatic arthritis under development.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-orthopedics-spin-off\">Orthopedics Spin\u2011Off<\/h2>\n\n\n\n<p>Johnson &amp; Johnson announced plans to spin off its orthopedics unit into a standalone company, <strong>DePuy\u202fSynthes<\/strong>. The transaction, subject to board and regulatory approval, is expected to take 18\u201324\u202fmonths. DePuy\u202fSynthes will generate <strong>USD\u202f9.2\u202fB<\/strong> in annual revenue, positioning it as the world\u2019s largest, most comprehensive orthopedics\u2011focused firm.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Leadership<\/strong> \u2013 Namal\u202fNawana named president; former chairman of Sapphiros and CEO of Smith\u202f&amp;\u202fNephew Plc.<\/li>\n\n\n\n<li><strong>Strategy<\/strong> \u2013 Duarto emphasized that a stand\u2011alone entity can \u201cdrive growth, innovation, and better margins\u201d in a lower\u2011growth orthopedics market.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements regarding future performance, product development, and regulatory approvals. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3Q25-Earnings-Press-Release-Final-Draft-10-13-25-3PM-With-Attachments.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 3Q25-Earnings-Press-Release-Final-Draft-10-13-25-3PM-With-Attachments.\"><\/object><a id=\"wp-block-file--media-85e435f1-0160-4482-8a08-163e04a724df\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3Q25-Earnings-Press-Release-Final-Draft-10-13-25-3PM-With-Attachments.pdf\">3Q25-Earnings-Press-Release-Final-Draft-10-13-25-3PM-With-Attachments<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3Q25-Earnings-Press-Release-Final-Draft-10-13-25-3PM-With-Attachments.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-85e435f1-0160-4482-8a08-163e04a724df\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced its third\u2011quarter results for 2025, showing a 5.4\u202f%&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43414,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,150,149,858],"class_list":["post-43410","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-jj","tag-johnson-johnson","tag-nyse-jnj"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Johnson &amp; Johnson Reports Robust Q3\u202f2025 Sales Growth, Boosts Full\u2011Year Outlook - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced its third\u2011quarter results for 2025, showing a 5.4\u202f% year\u2011on\u2011year (YoY) increase in constant\u2011currency sales to USD\u202f23.99\u202fbillion. The U.S. market grew 6.2\u202f% to USD\u202f13.7\u202fbillion, while international markets rose 4.4\u202f% to USD\u202f10.29\u202fbillion. Chief Executive Officer Joaquin\u202fDuato described the company as entering \u201ca new era of accelerated growth and innovation\u201d thanks to its expanding drug and device portfolio.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43410\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Johnson &amp; Johnson Reports Robust Q3\u202f2025 Sales Growth, Boosts Full\u2011Year Outlook\" \/>\n<meta property=\"og:description\" content=\"Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) announced its third\u2011quarter results for 2025, showing a 5.4\u202f% year\u2011on\u2011year (YoY) increase in constant\u2011currency sales to USD\u202f23.99\u202fbillion. The U.S. market grew 6.2\u202f% to USD\u202f13.7\u202fbillion, while international markets rose 4.4\u202f% to USD\u202f10.29\u202fbillion. Chief Executive Officer Joaquin\u202fDuato described the company as entering \u201ca new era of accelerated growth and innovation\u201d thanks to its expanding drug and device portfolio.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43410\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-15T07:42:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-15T07:42:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1507.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43410#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43410\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Johnson &amp; Johnson Reports Robust Q3\u202f2025 Sales Growth, Boosts Full\u2011Year Outlook\",\"datePublished\":\"2025-10-15T07:42:31+00:00\",\"dateModified\":\"2025-10-15T07:42:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43410\"},\"wordCount\":385,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43410#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1507.webp\",\"keywords\":[\"Finanical Reports\",\"J&amp;J\",\"Johnson &amp; Johnson\",\"NYSE: JNJ\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43410#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43410\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43410\",\"name\":\"Johnson &amp; Johnson Reports Robust Q3\u202f2025 Sales Growth, Boosts Full\u2011Year Outlook - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43410#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43410#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1507.webp\",\"datePublished\":\"2025-10-15T07:42:31+00:00\",\"dateModified\":\"2025-10-15T07:42:32+00:00\",\"description\":\"Johnson & Johnson (J&J, NYSE: JNJ) announced its third\u2011quarter results for 2025, showing a 5.4\u202f% year\u2011on\u2011year (YoY) increase in constant\u2011currency sales to USD\u202f23.99\u202fbillion. The U.S. market grew 6.2\u202f% to USD\u202f13.7\u202fbillion, while international markets rose 4.4\u202f% to USD\u202f10.29\u202fbillion. Chief Executive Officer Joaquin\u202fDuato described the company as entering \u201ca new era of accelerated growth and innovation\u201d thanks to its expanding drug and device portfolio.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43410#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43410\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43410#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1507.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1507.webp\",\"width\":1080,\"height\":608,\"caption\":\"Johnson & Johnson Reports Robust Q3\u202f2025 Sales Growth, Boosts Full\u2011Year Outlook\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43410#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Johnson &amp; Johnson Reports Robust Q3\u202f2025 Sales Growth, Boosts Full\u2011Year Outlook\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Johnson &amp; Johnson Reports Robust Q3\u202f2025 Sales Growth, Boosts Full\u2011Year Outlook - Insight, China&#039;s Pharmaceutical Industry","description":"Johnson & Johnson (J&J, NYSE: JNJ) announced its third\u2011quarter results for 2025, showing a 5.4\u202f% year\u2011on\u2011year (YoY) increase in constant\u2011currency sales to USD\u202f23.99\u202fbillion. The U.S. market grew 6.2\u202f% to USD\u202f13.7\u202fbillion, while international markets rose 4.4\u202f% to USD\u202f10.29\u202fbillion. Chief Executive Officer Joaquin\u202fDuato described the company as entering \u201ca new era of accelerated growth and innovation\u201d thanks to its expanding drug and device portfolio.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43410","og_locale":"en_US","og_type":"article","og_title":"Johnson &amp; Johnson Reports Robust Q3\u202f2025 Sales Growth, Boosts Full\u2011Year Outlook","og_description":"Johnson & Johnson (J&J, NYSE: JNJ) announced its third\u2011quarter results for 2025, showing a 5.4\u202f% year\u2011on\u2011year (YoY) increase in constant\u2011currency sales to USD\u202f23.99\u202fbillion. The U.S. market grew 6.2\u202f% to USD\u202f13.7\u202fbillion, while international markets rose 4.4\u202f% to USD\u202f10.29\u202fbillion. Chief Executive Officer Joaquin\u202fDuato described the company as entering \u201ca new era of accelerated growth and innovation\u201d thanks to its expanding drug and device portfolio.","og_url":"https:\/\/flcube.com\/?p=43410","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-15T07:42:31+00:00","article_modified_time":"2025-10-15T07:42:32+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1507.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43410#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43410"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Johnson &amp; Johnson Reports Robust Q3\u202f2025 Sales Growth, Boosts Full\u2011Year Outlook","datePublished":"2025-10-15T07:42:31+00:00","dateModified":"2025-10-15T07:42:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43410"},"wordCount":385,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43410#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1507.webp","keywords":["Finanical Reports","J&amp;J","Johnson &amp; Johnson","NYSE: JNJ"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43410#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43410","url":"https:\/\/flcube.com\/?p=43410","name":"Johnson &amp; Johnson Reports Robust Q3\u202f2025 Sales Growth, Boosts Full\u2011Year Outlook - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43410#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43410#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1507.webp","datePublished":"2025-10-15T07:42:31+00:00","dateModified":"2025-10-15T07:42:32+00:00","description":"Johnson & Johnson (J&J, NYSE: JNJ) announced its third\u2011quarter results for 2025, showing a 5.4\u202f% year\u2011on\u2011year (YoY) increase in constant\u2011currency sales to USD\u202f23.99\u202fbillion. The U.S. market grew 6.2\u202f% to USD\u202f13.7\u202fbillion, while international markets rose 4.4\u202f% to USD\u202f10.29\u202fbillion. Chief Executive Officer Joaquin\u202fDuato described the company as entering \u201ca new era of accelerated growth and innovation\u201d thanks to its expanding drug and device portfolio.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43410#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43410"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43410#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1507.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1507.webp","width":1080,"height":608,"caption":"Johnson & Johnson Reports Robust Q3\u202f2025 Sales Growth, Boosts Full\u2011Year Outlook"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43410#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Johnson &amp; Johnson Reports Robust Q3\u202f2025 Sales Growth, Boosts Full\u2011Year Outlook"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1507.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43410","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43410"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43410\/revisions"}],"predecessor-version":[{"id":43415,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43410\/revisions\/43415"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43414"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43410"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43410"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}